Psychedelic Business Spotlight: August 6, 2021
Business
Another clinic gets approval to conduct MDMA research, and new psychedelic research facilities open in Australia and the U.S., plus two game-changing psilocybin patents.
In this episode, Sacha Hebbert sits with the CEO, Benjamin Lightburn of Filament Health, to discuss the ins and outs of being a licensed dealer of naturally derived psilocybin in Canada and internationally.
In this episode, Sacha Hebbert sits with the CEO, Benjamin Lightburn of Filament Health, to discuss the ins and outs of being a licensed dealer of naturally derived psilocybin in Canada and internationally.
Episode Summary
Filament Health produces non-synthetic psychedelic substances for research and treatment. They’re known as the first lab to have non-synthesized psilocybin for clinical trials and hope to show the efficacy of naturally derived psychedelics. Benjamin explains some current clinical trials as they test out the difference between oral and sublingual administration of psilocybin. We also dive into the Special Access Program and how to apply to Health Canada for access to non-approved drugs for experimental treatments of depression.
You can keep in touch with Benjamin on Twitter (@benlightburn) or with Filament Health on Twitter (@FilamentHealth), Instagram (@FilamentHealth), or on their website.
Related News
Trackbacks & Pingbacks
[…] psilocybin mushroom spores they should get a s.56 exemption as well as the applicable licenses (dealer’s license or producer’s license) for dealing with those spores. Neglecting this precaution could result in criminal charges under […]
Leave a Reply
Want to join the discussion?Feel free to contribute!